Inken Piro

Dr. Inken Piro

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2026 in Science
Verified
Journal Article
Closed access
YCYang Chen
Yang Chen
MKMarinus Kloos
Marinus Kloos
ZVZsuzsanna Varga
Zsuzsanna Varga
YZYonghai Zhang
Yonghai Zhang
IPInken Piro
Inken Piro
AKArthur Konnerth
Arthur Konnerth
Deciphering thalamocortical (TC) activation at the level of individual synapses is essential to understanding how the cortex processes sensory information. In this work, we studied TC computation underlying the emergence of orientation selectivity in the mammalian primary visual cortex (V1). Using two-photon glutamate imaging and optogenetic cortical silencing in vivo, we identified and characterized TC synapses onto mouse V1 layer 4 neurons. We found that TC- but not corticocortical-recipient spines lacked postsynaptic Ca 2+ signals. Our results directly validate the core predictions of Hubel and Wiesel’s feedforward model and reveal distinctive synaptic properties that are critical for cortical computation and plasticity.

22 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TZTaraneh Sadat Zavvar
Taraneh Sadat Zavvar
GSGiulia Santo
Giulia Santo
LGLeonhard Gruber
Leonhard Gruber
AKAriane Kronthaler
Ariane Kronthaler
JHJudith Hagenbuchner
Judith Hagenbuchner
EGElisabeth Von Guggenberg
Elisabeth Von Guggenberg
Background/Objectives: Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors (NETs), enabling targeted radiation delivery via radiolabeled peptides. Small cell lung cancer (SCLC) remains a major therapeutic challenge due to its aggressive nature and poor prognosis. Despite advances, relapse rates are high and effective therapies are limited. We previously demonstrated the diagnostic potential of the cholecystokinin-2 receptor (CCK2R)-targeting minigastrin analog [68Ga]Ga-DOTA-MGS5 in PET/CT imaging of different NETs. Building on this, we developed and evaluated [177Lu]Lu-DOTA-MGS5 as a therapeutic PRRT agent. Methods: Preclinical studies investigating the receptor-mediated cellular internalization and intracellular distribution over time in A431 cells with and without CCK2R expression were performed using the fluorescent tracer ATTO-488-MGS5. Short- and long-term cytotoxic effects of [177Lu]Lu-DOTA-MGS5 were evaluated on the same cell line using trypan blue exclusion and clonogenic survival assays. CCK2R expression was assessed by immunohistochemistry in 42 SCLC tissue specimens. In addition, the first PRRT with [177Lu]Lu-DOTA-MGS5 was conducted in a patient with extensive disease SCLC (ED-SCLC) after confirming CCK2R-positive uptake in [68Ga]Ga-DOTA-MGS5 PET/CT. Results: Rapid binding and internalization into A431-CCK2R cells, with progressive accumulation in intracellular compartments, was observed for ATTO-488-MGS5. Short-term irradiation effects of [177Lu]Lu-DOTA-MGS5 were comparable for 4 h and 24 h incubation and were between the effects obtained with 2 and 4 Gy of external beam radiotherapy (EBRT). Clonogenic survival of A431-CCK2R cells incubated with increasing activity of [177Lu]Lu-DOTA-MGS5 decreased in a dose-dependent manner. Immunohistochemistry on SCLC specimens confirmed moderate to high CCK2R expression in 16 out of 42 SCLC samples. In the first patient with SCLC treated with four cycles of [177Lu]Lu-DOTA-MGS5 with a total activity of 17.2 GBq, an improvement in clinical symptoms was observed. Conclusions: The preclinical and clinical results confirm the feasibility of [177Lu]Lu-DOTA-MGS5 PRRT in patients with SCLC and support further clinical studies investigating the therapeutic value and clinical applicability of this new CCK2R-targeted theranostic approach in larger patient cohorts.